Τίτλος:
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). Patients and Methods: Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Assessments included progression-free survival, overall survival, objective response rate, and safety. We also evaluated effectiveness based on number of risk factors, age, and performance status (PS), as well as safety in older and younger patients. Results: Three hundred sixty three and 343 intermediate-risk MSKCC and IMDC patients were included, respectively. The median progression-free survival was 13.8 months (95% confidence interval [CI], 10.7-18.1 months) and 7.4 months (95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 13.1 months (95% CI, 10.7-18.1 months) and 8.1 months (95% CI, 6.4-10.7 months) for patients with 1 and 2 IMDC risk factors, respectively. The median overall survival was not reached and was 15.2 months (95% CI, 12.3-26.5 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 33.9 months (95% CI, 33.9 months to not estimable) and 19.4 months (95% CI, 14.3 months to not estimable) with 1 and 2 IMDC risk factors, respectively. A lower overall response rate was observed with Eastern Cooperative Oncology Group PS ≥ 2 (vs. PS < 2). All-grade treatment-related adverse events occurred in approximately 63% of patients, and the safety profile among older and younger patients was similar. Conclusions: Outcomes with pazopanib in intermediate-risk patients suggest that patients can be further stratified by number of risk factors (1 vs. 2) and Eastern Cooperative Oncology Group PS (< 2 vs. ≥ 2) to more accurately predict outcomes. © 2019
Patients with intermediate-risk advanced renal cell carcinoma are a heterogeneous population, having either 1 or 2 risk factors. It is unclear whether all patients in this risk category should be treated similarly. A secondary analysis of the PRINCIPAL study of pazopanib found that patients can be stratified by number of risk factors and Eastern Cooperative Oncology Group performance status to more accurately predict outcomes. © 2019
Συγγραφείς:
Procopio, G.
Bamias, A.
Schmidinger, M.
Hawkins, R.
Sánchez, A.R.
Estevez, S.V.
Srihari, N.
Kalofonos, H.
Bono, P.
Pisal, C.B.
Hirschberg, Y.
Dezzani, L.
Ahmad, Q.
Rodriguez, C.S.
Jonasch, E.
Περιοδικό:
Clinical Genitourinary Cancer
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
alanine aminotransferase; alpha interferon; aspartate aminotransferase; calcium; hemoglobin; interleukin 2; lactate dehydrogenase; pazopanib; thyrotropin; angiogenesis inhibitor; pazopanib; pyrimidine derivative; sulfonamide, adult; advanced cancer; aged; Article; calcium blood level; cancer prognosis; clinical trial; diarrhea; drug efficacy; drug safety; female; follow up; hemoglobin blood level; human; hypertension; hypothyroidism; Karnofsky Performance Status; kidney metastasis; liver toxicity; major clinical study; male; nausea; neutrophil count; observational study; overall survival; platelet count; progression free survival; prospective study; renal cell carcinoma; risk factor; side effect; thyrotropin blood level; very elderly; vomiting; kidney tumor; metastasis; middle aged; pathology; patient safety; prognosis; renal cell carcinoma; survival rate; young adult, Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Safety; Prognosis; Prospective Studies; Pyrimidines; Risk Factors; Sulfonamides; Survival Rate; Young Adult
DOI:
10.1016/j.clgc.2019.01.018
